retatrutide trial dosing just posted the biggest weight-loss numbers ever recorded for a drug — 28.3% (≈70 lb) average in Phase 3, with 45% of people hitting 30%+ loss, territory once reserved for bariatric retatrutide clinical trial dosing frequency

Facing increasing revenue pressures, the state expects to save $17 million per year from the move

The pharmacokinetics explain everything

They are not a substitute for nutrition, resistance training, medical supervision, or long-term planning

2025 Feb;39(2):e153-e154

American Board of Pediatrics (ABP) Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.50 MOC points in the American Board of Pediatrics (ABP) Maintenance of Certification (MOC) program

But Your Honor, when you control for weight loss, those effects disappear or diminish substantially